PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Adding immunotherapy to chemotherapy regimen improves survival in metastatic bladder cancer patients

The first improvement for these patients; promises to be a new standard of care

2023-10-22
(Press-News.org) New York, NY (October 22, 2023) — A clinical trial co-led by Mount Sinai researchers is the first to show that using chemotherapy with immunotherapy resulted in improved survival in patients with an advanced type of bladder cancer. The results were simultaneously reported in The New England Journal of Medicine and at the annual meeting of the European Society for Medical Oncology.

The randomized phase 3 trial, named ”CheckMate 901,” showed significantly improved outcomes in patients who received the immunotherapy nivolumab with a combination of the chemotherapies gemcitabine and cisplatin, compared to those who received the chemotherapy combination alone. The number of patients who had no evidence of disease after treatment was nearly twice as high in the group that received chemotherapy with nivolumab, a monoclonal antibody immune checkpoint inhibitor that harnesses the immune system to fight cancer.

“No new agent when added to first-line standard-of-care cisplatin-based chemotherapy has improved overall survival in metastatic urothelial carcinoma until now,” said Matthew Galsky, MD, Co-Director of the Center of Excellence for Bladder Cancer at The Tisch Cancer Institute, a part of the Tisch Cancer Center at Mount Sinai, and senior author of the publication. “These results support nivolumab plus cisplatin-based chemo as a new standard approach for the treatment of metastatic urothelial cancer.”

A total of 608 patients participated in this trial. Both overall survival and progression-free survival were higher in patients on the immunotherapy-chemotherapy regimen after almost three years. The median duration of complete response in those patients was 37.1 months compared to 13.2 months for patients on just chemotherapy.

This trial was funded by Bristol Myers Squibb in collaboration with Ono Pharmaceutical Company Ltd. The trial was an international collaboration among several institutions.

 

About the Mount Sinai Health System

Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with more than 43,000 employees working across eight hospitals, over 400 outpatient practices, nearly 300 labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time — discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.

Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 7,300 primary and specialty care physicians; 13 joint-venture outpatient surgery centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and more than 30 affiliated community health centers. We are consistently ranked by U.S. News & World Report's Best Hospitals, receiving high "Honor Roll" status, and are highly ranked: No. 1 in Geriatrics and top 20 in Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Neurology/Neurosurgery, Orthopedics, Pulmonology/Lung Surgery, Rehabilitation, and Urology. New York Eye and Ear Infirmary of Mount Sinai is ranked No. 12 in Ophthalmology. U.S. News & World Report’s “Best Children’s Hospitals” ranks Mount Sinai Kravis Children's Hospital among the country’s best in several pediatric specialties.

For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.

END


ELSE PRESS RELEASES FROM THIS DATE:

Dual-action drug produces positive results in patients with advanced neuroendocrine tumors, trial finds

2023-10-22
Cabozantinib, which targets tumor cell growth and tumor blood vessel growth, sharply improved progression-free survival over placebo in patients with extra-pancreatic and pancreatic neuroendocrine tumors Boston - A drug that simultaneously strikes cancer cells' growth circuits and pipeline to the bloodstream produced encouraging results in a clinical trial involving patients with advanced neuroendocrine tumors, according to a study led by Dana-Farber Cancer Institute investigators. Jennifer Chan, MD, MPH, director of the Program ...

Alliance presents detailed results from phase III CABINET pivotal Trial evaluating cabozantinib in advanced neuroendocrine tumors at ESMO 2023

Alliance presents detailed results from phase III CABINET pivotal Trial evaluating cabozantinib in advanced neuroendocrine tumors at ESMO 2023
2023-10-22
The Alliance for Clinical Trials in Oncology today announced detailed results will be presented at ESMO 2023 from CABINET (A021602), a phase III pivotal trial evaluating cabozantinib compared with placebo in two cohorts of patients with previously treated neuroendocrine tumors: one cohort of patients with advanced pancreatic neuroendocrine tumors (pNET) and a second cohort of patients with advanced extra-pancreatic NET (epNET). The study met the primary objective for each cohort, demonstrating that cabozantinib provided dramatic improvements in median progression-free survival (PFS) for the patients in the pNET and epNET cohorts. ...

ESMO: Pre- and post-surgical immunotherapy improves outcomes for patients with operable lung cancer

ESMO: Pre- and post-surgical immunotherapy improves outcomes for patients with operable lung cancer
2023-10-21
MADRID ― Compared with pre-surgical (neoadjuvant) chemotherapy alone, adding perioperative immunotherapy – given before and after surgery – significantly improved event-free survival (EFS) in patients with resectable early-stage non-small cell lung cancer (NSCLC). Results from the Phase III CheckMate 77T study were presented today at the 2023 European Society for Medical Oncology (ESMO) Congress by researchers from The University of Texas MD Anderson Cancer Center. At a median follow-up of 25.4 months, the median EFS with chemotherapy alone was 18.4 months, while the median had not yet been reached for patients receiving perioperative nivolumab, meaning EFS was prolonged ...

Kidney cancer study shows improved outcomes for patients with advanced disease when treated with belzutifan over everolimus

2023-10-21
Boston – Belzutifan significantly reduced the risk of progression of clear cell renal cell carcinoma (ccRCC), the most common type of kidney cancer, in patients previously treated with immune checkpoint inhibitors and anti-angiogenic therapies compared with everolimus in a phase 3 clinical trial. The trial, led by Toni K. Choueiri, MD, Director of the Lank Center for Genitourinary Cancer at Dana-Farber Cancer Institute, showed the risk of progression was reduced by 25-26%. The results were presented at the annual European Society for Medical Oncology (ESMO) Congress on October ...

THE LANCET JOURNALS: Papers publishing during the European Society for Medical Oncology Congress 2023 (#ESMO 2023), 20th – 24th October 2023

2023-10-21
The following Lancet papers will be presented at the European Society for Medical Oncology Congress 2023 (#ESMO 2023). The conference will take place between Friday 20th – Tuesday 24th October 2023.  Contact details for corresponding authors are provided should you wish to arrange an interview with the authors. Funding information is listed on the first page of each Article. **Embargo: 13.00 [BST] / 14.00 [CEST] Friday 20th October 2023** The Lancet: Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase ...

Highest risk patients with clear-cell renal cell carcinoma benefit from adjuvant everolimus

2023-10-21
A secondary analysis from the SWOG S0931 EVEREST trial has found that in the subgroup of patients with clear-cell renal cell carcinoma (RCC) who were at very-high risk of recurrence, those who were treated with everolimus after surgery had a statistically significant improvement in recurrence-free survival compared to patients getting placebo after surgery. The results will be presented at the European Society of Medical Oncology (ESMO) Congress 2023 in Madrid, Spain, on Oct. 23, 2023 (poster 1887P) by Primo N. Lara, Jr., MD, lead author on the abstract. ...

American Academy of Pediatrics sounds the alarm on excessive noise and risks to children’s hearing in updated policy statement

2023-10-21
  Media contacts: Lisa Black, lblack@aap.org; or Adam Alexander, aalexander@aap.org     The parent’s universal cry in response to loud music-- “Turn that thing down!” -- is well-founded, as evidence shows that children and teens risk hearing loss by cranking up their personal listening devices. What families may not realize is that children are exposed to potentially harmful noise from infancy and that the effects are cumulative over a lifetime.   The American Academy of Pediatrics discusses the common sources and effects of noise, from infant sleep ...

Bioengineering team wins health care innovation competition

Bioengineering team wins health care innovation competition
2023-10-20
Four senior bioengineering students at The University of Texas at Arlington have won the Biomedical Engineering Society (BMES) Coulter College for Healthcare Innovation competition for their work on an early detection device for atrial fibrillation. Brady Killham, Juan Ramirez, Jeannette Santos and Michael Ikefuna, all seniors in UTA’s Bioengineering Department, earned the Best Overall award for their plan to develop FibGuard, a wearable, non-invasive atrial fibrillation early detection device. UTA competed against teams from Vanderbilt, Purdue, Virginia Tech, Wake Forest, Texas A&M, the University of Oklahoma and Rensselaer Polytechnic ...

Antimicrobial peptides modulate lung injury by altering the intestinal microbiota

Antimicrobial peptides modulate lung injury by altering the intestinal microbiota
2023-10-20
BIRMINGHAM, Ala. – Lung development in the fetus occurs at low oxygen tension in the womb, but after a very premature birth, the partly developed lungs of the tiny infants experience far greater oxygen tensions even without the prolonged supplemental oxygen that is often required. This can produce well-known disastrous effects on the structure and function of the neonatal lung, causing the serious lung condition of bronchopulmonary dysplasia in high-risk premature infants. Using a neonatal mouse model, researchers ...

Diagnosis and management of postoperative wound infections in the head and neck region

Diagnosis and management of postoperative wound infections in the head and neck region
2023-10-20
“The majority of wound infections often manifest themselves immediately postoperatively, so close followup should take place [...]” BUFFALO, NY- October 20, 2023 – A new research perspective was published in Oncoscience (Volume 10) on October 4, 2023, entitled, “Diagnosis and management of postoperative wound infections in the head and neck region.” In everyday clinical practice at a department for oral and maxillofacial surgery, a large number of surgical procedures in the head and neck region take place under both outpatient and inpatient conditions. The basis ...

LAST 30 PRESS RELEASES:

Thirty years of research shows increased resistance in fungi

Junk food ‘avoids advertising regulation’ with top level UK sports sponsorship

Banking on AI while committed to net zero is ‘magical thinking’, claims report on energy costs of big tech

Ancient river systems reveal Mars was wetter than we thought

Online toolkit to help parents of autistic children improve dental health

The psychological and neurological parallels between sports fandom and religious devotion

Agricultural liming in the US is a large CO2 sink, say researchers

Seaside more likely to make us nostalgic than green places, study finds

Psilocybin delays aging, extends lifespan, Emory study suggests

Buck Institute awarded DARPA contract to pioneer next-gen AI modeling platform

Orange is the new aphrodisiac—for guppies

Murals boost Cincinnati’s vitality, community development

Ad blockers may be showing users more problematic ads, NYU Tandon study finds

Verbal response time reveals hidden sleepiness in older adults

University of Maryland School of Medicine launches groundbreaking study on THC/CBD therapy for dementia-related agitation at end of life

Targeting stem-property and vasculogenic mimicry for sensitizing paclitaxel therapy of triple-negative breast cancer by biomimetic codelivery

SRSF7 promotes pulmonary fibrosis through regulating PKM alternative splicing in lung fibroblasts

Psychological stress-activated NR3C1/NUPR1 axis promotes ovarian tumor metastasis

An anti-complement homogeneous polysaccharide from Houttuynia cordata ameliorates acute pneumonia with H1N1 and MRSA coinfection through rectifying Treg/Th17 imbalance in the gut–lung axis and NLRP3 i

ALKBH3-regulated m1A of ALDOA potentiates glycolysis and doxorubicin resistance of triple negative breast cancer cells

A photodynamic nanohybrid system reverses hypoxia and augment anti-primary and metastatic tumor efficacy of immunotherapy

Acta Pharmaceutica Sinica B Volume 15, Issue 6 Publishes

From injury to agony: Scientists discover brain pathway that turns pain into suffering

Molecular simulations show graphite ‘hijacks’ diamond formation through unexpected crystallization pathways

Scientific breakthrough uses cold atoms to unlock cosmic mysteries 

First-of-its-kind journal facilitates rapid publication of AI research

AI tool helps improve detection of cardiac amyloidosis

Loneliness predicts poor mental and physical health outcomes

Keeping the photon in the dark

FDA-approved drugs could make nano-medicine safer, study finds

[Press-News.org] Adding immunotherapy to chemotherapy regimen improves survival in metastatic bladder cancer patients
The first improvement for these patients; promises to be a new standard of care